Docetaxel plus cetuximab biweekly is an active regimen for the first-line treatment of patients with recurrent/metastatic head and neck cancer
about
Modified biweekly cisplatin, docetaxel plus cetuximab (TPEx) as first-line treatment for patients with recurrent/metastatic head and neck cancer.A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.Efficacy and Tolerance of Cetuximab Alone or Combined with Chemotherapy in Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: An Open Study of 14 Patients.
P2860
Docetaxel plus cetuximab biweekly is an active regimen for the first-line treatment of patients with recurrent/metastatic head and neck cancer
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 September 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Docetaxel plus cetuximab biwee ...... etastatic head and neck cancer
@en
Docetaxel plus cetuximab biwee ...... tastatic head and neck cancer.
@nl
type
label
Docetaxel plus cetuximab biwee ...... etastatic head and neck cancer
@en
Docetaxel plus cetuximab biwee ...... tastatic head and neck cancer.
@nl
prefLabel
Docetaxel plus cetuximab biwee ...... etastatic head and neck cancer
@en
Docetaxel plus cetuximab biwee ...... tastatic head and neck cancer.
@nl
P2093
P2860
P356
P1433
P1476
Docetaxel plus cetuximab biwee ...... etastatic head and neck cancer
@en
P2093
Doris Posch
Gabriela Kornek
Hannah Fuchs
Johannes Pammer
Marie-Bernadette Aretin
Thorsten Fuereder
P2860
P2888
P356
10.1038/SREP32946
P407
P577
2016-09-06T00:00:00Z
P6179
1001459529